Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$119.79 USD
+1.35 (1.14%)
Updated Oct 31, 2025 03:59 PM ET
After-Market: $119.74 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GILD 119.79 +1.35(1.14%)
Will GILD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GILD
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
Other News for GILD
Gilead price target raised to $145 from $127 at Truist
Gilead price target raised by $18 at Truist, here's why
Is GILD likely to continue higher? Crossed Above 20 Day Moving Average shows up after advancing 1.14%
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?